Form 4: Director Barnes Acquires VNRX Shares via RSU Vesting

VOLITIONRX LTD Director Phillip Barnes acquired 12,000 common shares through the vesting of restricted stock units, increasing his direct beneficial ownership to 67,368 shares.

Summary

• Phillip Barnes, a Director of VOLITIONRX LTD (VNRX), reported a change in beneficial ownership.
• On January 22, 2026, Barnes acquired 12,000 shares of common stock at a price of $0.
• This acquisition resulted from the vesting of restricted stock units (RSUs) awarded under the company's 2024 Stock Incentive Plan.
• The RSUs were initially awarded on March 17, 2025, totaling 40,000 units, subject to performance and time-based vesting.
• 12,000 RSUs vested due to the achievement of certain corporate performance goals.
• These 12,000 vested RSUs are further subject to a 3-year time-based vesting schedule, with 4,000 units scheduled to vest on March 17, 2026, 2027, and 2028, respectively.
• The remaining 28,000 RSUs did not vest and were cancelled on June 30, 2025, and January 22, 2026.
• Following this transaction, Barnes directly beneficially owns 67,368 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a significant portion of RSUs (28,000 out of 40,000) did not vest, the vesting of 12,000 RSUs indicates that some corporate performance goals were met, which is a positive signal. The transaction itself is a standard compensation event for a director.

Positives

• 12,000 restricted stock units (RSUs) vested, indicating the achievement of certain corporate performance goals.
• The director's beneficial ownership of common stock increased by 12,000 shares, aligning insider interests with shareholders.

Negatives

• 28,000 restricted stock units (RSUs) did not vest and were cancelled, indicating that some performance goals were not met.

Future Outlook

The vesting schedule for the 12,000 RSUs indicates future share issuances to the director in three equal installments on March 17, 2026, 2027, and 2028, contingent on continued service.

Industry Context

This Form 4 filing reflects a routine insider transaction related to executive compensation, common across publicly traded companies. The use of restricted stock units (RSUs) tied to performance and time-based vesting is a standard practice to align executive incentives with shareholder value and long-term company performance within the biotechnology and diagnostics industry, where VOLITIONRX LTD operates.

Stakeholder Impact

• Shareholders: The vesting and subsequent issuance of shares will result in a minor dilution, but also signals that some performance targets were met. Increased insider ownership can be seen as a positive alignment of interests.
• Employees: The RSU plan is part of the company's compensation strategy, potentially impacting employee morale and retention if similar plans are offered.

Next Steps

• Phillip Barnes will receive 4,000 shares of common stock on March 17, 2026, upon the first time-based vesting installment.
• Phillip Barnes will receive 4,000 shares of common stock on March 17, 2027, upon the second time-based vesting installment.
• Phillip Barnes will receive 4,000 shares of common stock on March 17, 2028, upon the third time-based vesting installment.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction related to director compensation through restricted stock units. While the vesting of 12,000 RSUs indicates some corporate performance goals were met, the cancellation of 28,000 RSUs suggests others were not. This event is a standard part of executive compensation and does not provide sufficient new information to warrant a change in investment thesis. Investors should continue to hold based on broader company fundamentals and market conditions, as this specific filing is unlikely to be a significant price driver.

Keywords

VOLITIONRX LTD, VNRX, Phillip Barnes, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Beneficial Ownership, Director Compensation, Stock Incentive Plan